Switch Over Study of Biosimilar AGA for Fabry Disease
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group,
baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA
BETA BS in patients with FD already treated and previously stabilized with Fabrazyme®.